Bluebird claims EU nod for rare disease therapy SkysonaBluebird bio has its first approval for Skysona (formerly Lenti-D), its gene therapy for children with the rare Share XBluebird claims EU nod for rare disease therapy Skysonahttps://pharmaphorum.com/news/bluebird-claims-eu-nod-for-rare-disease-therapy-skysona/
CHMP backs bluebird bio’s gene therapy for rare disease ALDUS biotech bluebird bio has had a challenging time in the last few months, so a recommendation for Share XCHMP backs bluebird bio’s gene therapy for rare disease ALDhttps://pharmaphorum.com/news/chmp-backs-bluebird-bios-gene-therapy-for-rare-disease-ald/
bluebird bio announces long-term data from CALD gene therapybluebird bio has announced new clinical trial data from its gene therapy for patients with cerebral adrenoleukodystrophy (CALD), Share Xbluebird bio announces long-term data from CALD gene therapyhttps://pharmaphorum.com/news/bluebird-announced-long-term-data-from-cald-gene-therapy/
